�Aperio Technologies, Inc., (Aperio), a world-wide leader in digital pathology for the healthcare and life sciences industry, has received clearance from the U.S. Food and Drug Administration (FDA) to market the ER and PR image analysis applications useable through its patented ScanScope� slide scanning system. The FDA-cleared immunohistochemistry (IHC) ikon analysis applications are intended to be used as an tending to pathologists in detecting and quantifying ER (estrogen receptor) and PR (lipo-Lutin receptor) protein expressions from digital swoop images created by Aperio's slide scanning systems.
Aperio's FDA clearance encompasses the company's complete digital pathology system, including ScanScope scanners for creating digital slide images from microscope slides, the SpectrumTM digital pathology information management system for managing, viewing, and analyzing digital slides, and the specific persona analysis applications which perform the machine-controlled scoring of ER and PR chest cancer digital slides.
"The addition of FDA exculpated ER/PR image analysis applications to our previously cleared applications for HER2 underscores our committedness to ply clinicians and breast cancer patients with the to the highest degree comprehensive entire-slide quantitative mental image analysis panel available anywhere," stated Dirk Soenksen, CEO of Aperio. "Aimed with these clearances, our customers can now take full advantage of our young digital IHC software to optimize their workflow and streamline reportage, while enjoying the benefits of quantitative image analytic thinking."
In 2007, Aperio achieved more than 125% gross sales growth through and through continued acceptance of its digital pathology platform crosswise a wide spectrum of clinical, inquiry and educational applications. Aperio has an installed foundation of more than 400 systems in 27 countries, including more than two-thirds of the top 15 rated U.S. hospitals, leading academic aesculapian centers and reference laboratories, and two-thirds of the top 15 pharmaceutical companies.
About Aperio
Aperio is digitizing pathology. We provide systems and services for digital pathology, which is an environs for the management and interpretation of pathology entropy that originates with the digitization of a glass slide. Aperio's award-winning ScanScope� slide scanning systems and Spectrum� digital pathology data management software package improve the efficiency and quality of pathology services for pathologists and other professionals. Applications include educational activity, remote screening, archival and retrieval, basic research, and image analysis. Aperio's products are FDA cleared for specific clinical applications, and are intended for inquiry and education use for other applications.
http://www.aperio.com
More information
Monday, 1 September 2008
Subscribe to:
Comments (Atom)